HAVCR2 and cancer: HAVCR2/TIM-3 has been reported to be upregulated in response to PD-1 blockade in various cancer models (31, 32), and overexpression of HAVCR2/TIM-3 and VISTA has been associated with lack of response to anti-PD-1/PD-L1–based therapies (33).